AptarGroup 3Q 2026: Revenue $1.02B, Net income $32.6M, EPS $0.51— 10-Q Summary
AptarGroup reported 3Q 2026 revenue of $1.02B, up 6% YoY, but net income fell 74.5% to $32.6M and EPS declined 73.4% to $0.51. Core sales grew 5%, led by Beauty and Closures. The company deconsolidated Russia operations and guided 4Q adjusted EPS to $1.39-$1.47.
How this was made
The 30-second read
Why it matters
Core sales growth in Beauty and Closures contrasts with a steep decline in net income and diluted EPS, while Q4 adjusted EPS guidance of $1.39 to $1.47 provides a concrete forward anchor for expectations.
Market read
Traders can update near-term expectations using the reported revenue/EPS deterioration and the stated Q4 adjusted EPS range.
What to watch
The summary mentions margin pressure and operational issues but does not quantify them; traders may need the 10-Q footnotes to determine whether the earnings drop is structural or temporary.
Background
The piece is a summary of AptarGroup’s Oct. 30, 2026 10-Q, covering 3Q 2026 results, segment/core sales commentary, Russia deconsolidation, and Q4 adjusted EPS guidance.
Ticker impact
AptarGroup reported 3Q 2026 net sales of $1.02B (+6% YoY) but net income fell 74.5% to $32.6M, with adjusted EPS guidance of $1.39 to $1.47 for Q4.
Likely choppy trading as investors weigh core sales growth against margin/earnings pressure and focus on whether Q4 guidance offsets the net income drop.
The article provides specific quarterly results (revenue, net income, EPS) plus forward adjusted EPS guidance, which are direct inputs to near-term valuation and expectations.
Market effects
Signals ongoing margin pressure risk in packaging and drug-delivery components even when demand in beauty/closures remains resilient.
North America mix and margin pressure are cited, which may influence regional peers’ near-term margin expectations.
Deconsolidation of Russia operations highlights ongoing geopolitical and reporting impacts for multinational consumer and pharma supply chains.
Counterpoint
The large net income decline may be driven by non-operating items or mix effects, so the market may focus more on core sales growth and the Q4 adjusted EPS range than on GAAP net income.
Key entities
- companyAptarGroup, Inc.
Packaging and drug-delivery components company reporting 3Q 2026 results and issuing Q4 adjusted EPS guidance.
